TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9184402

Group type: COMPARATOR
Intervention: PEG-Hirudin 0.3 mg/kg i.v. injection
Number of subjects: 75

Group type: COMPARATOR
Intervention: PEG-Hirudin 0.01 mg/kg/h continuous i.v. infusion
Number of subjects: 75

Group type: COMPARATOR
Intervention: PEG-Hirudin 0.02 mg/kg/h continuous i.v. infusion
Number of subjects: 75

Group type: COMPARATOR
Intervention: PEG-Hirudin 0.05 to 0.6 mg/kg subcutaneous doses
Number of subjects: 75

Group type: COMPARATOR
Intervention: PEG-Hirudin 0.2 to 0.4 mg/kg once daily subcutaneous for five days
Number of subjects: 75

Group type: COMPARATOR
Intervention: PEG-Hirudin 0.3 mg/kg i.v. bolus followed by daily s.c. injections
Number of subjects: 75

Group type: COMPARATOR
Intervention: APTT reagents tested (BioMérieux Silimat and IL-ellagic acid)
Number of subjects: 75

Group type: COMPARATOR
Intervention: PEG-Hirudin
Number of subjects: 75

Group type: COMPARATOR
Intervention: PEG-Hirudin compared to non-conjugated r-hirudin
Number of subjects: 75
Study: 8264145

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day, increasing to 20 to 40 mg/day as required)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3987180

Group type: COMPARATOR
Intervention: Intravenous nifedipine infusion (4.5 mg in 45 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral nifedipine (20 mg sustained-release tablet)
Number of subjects: 20
Study: 29530513

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nails (R-IMN)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis (MIPO)
Number of subjects: 60
Study: 26460743

Group type: EXPERIMENTAL
Intervention: Immediately loaded 1P implants
Number of subjects: 33

Group type: COMPARATOR
Intervention: Delayed loaded 1P implants
Number of subjects: 33

Group type: COMPARATOR
Intervention: 2P implants
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 33
Study: 24824661

Group type: EXPERIMENTAL
Intervention: Lithium, 300 mg twice daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 22864465

Group type: EXPERIMENTAL
Intervention: Creatine (5 g/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 20121745

Group type: EXPERIMENTAL
Intervention: Sotrastaurin + standard-exposure tacrolimus (SET)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Sotrastaurin + reduced-exposure tacrolimus (RET)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control (SET + mycophenolic acid [MPA])
Number of subjects: 216
Study: 17868655

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 16312177

Group type: EXPERIMENTAL
Intervention: FCT SQV (two 500 mg tablets)
Number of subjects: 100

Group type: COMPARATOR
Intervention: HC SQV (five 200 mg capsules)
Number of subjects: 100
Study: 12732885

Group type: EXPERIMENTAL
Intervention: Standard-dose (SD) CSA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose (LD) CSA
Number of subjects: 100

Group type: COMPARATOR
Intervention: No CSA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CSA (both SD and LD)
Number of subjects: 100
Study: 10469776

Group type: EXPERIMENTAL
Intervention: 50-microg salmeterol powder via Diskhaler
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50-microg salmeterol powder via Diskus
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8733205

Group type: EXPERIMENTAL
Intervention: High treatment specificity and high delta sleep ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High treatment specificity and low delta ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low treatment specificity and low delta ratio
Number of subjects: 0
Study: 1905629

Group type: EXPERIMENTAL
Intervention: Glucose stimulation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Arginine infusion (15 mg kg-1 min-1) during hyperglycaemic clamps
Number of subjects: 8
Study: 6679363

Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate for hookworm
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis for malaria
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metrifonate for S. haematobium
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 31562751

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 100
Study: 29105841

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1001
Study: 26434752

Group type: EXPERIMENTAL
Intervention: Pharmacist involvement (face-to-face medication reconciliation, patient-specific pharmaceutical care plan, discharge counseling, postdischarge phone calls on days 3, 14, and 30)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Usual hospital standard of care (control group)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Pharmacist involvement
Number of subjects: 278
Study: 24618831

Group type: COMPARATOR
Intervention: Community action interventions including community engagement, general practitioner training in alcohol screening and brief intervention, media campaign, and others implemented from 2005 to 2009.
Number of subjects: 20
Study: 22581199

Group type: EXPERIMENTAL
Intervention: Zotarolimus‐eluting Resolute stent
Number of subjects: 1709

Group type: COMPARATOR
Intervention: Everolimus‐eluting XIENCE V stent
Number of subjects: 1709
Study: 20370970

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring and/or exposure therapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 77
Study: 17395868

Group type: EXPERIMENTAL
Intervention: 4 mg intravenous zoledronate (n=14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 27
Study: 14961215

Group type: EXPERIMENTAL
Intervention: High-dose CEE (1.25 mg/day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard-dose CEE (0.625 mg/day)
Number of subjects: 88
Study: 12244081

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DMO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 0
Study: 9690572

Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7862229

Group type: EXPERIMENTAL
Intervention: Enoxaparin at a dose of 0.5 mg/kg (50 U1 Anti‐Xa/kg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Increased doses of enoxaparin between 0.6 and 0.9 mg/kg as needed
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mean dose of enoxaparin at the end of the study
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enoxaparin treatment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enoxaparin at 0.5 mg/kg
Number of subjects: 72
Study: 2658689

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg iv) followed by succinylcholine 20 mg iv
Number of subjects: 22

Group type: COMPARATOR
Intervention: Succinylcholine 20 mg iv alone
Number of subjects: 22
Study: 30615038

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 1665

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 1665

Group type: EXPERIMENTAL
Intervention: Follow-up infarct volume (FIV)
Number of subjects: 1665
Study: 27977300

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) program
Number of subjects: 547

Group type: COMPARATOR
Intervention: Resistive rubber-band running program
Number of subjects: 547
Study: 25529832

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 1864
Study: 23524622

Group type: EXPERIMENTAL
Intervention: Papaya preparation (Caricol®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21518736

Group type: EXPERIMENTAL
Intervention: Sevoflurane-based anaesthesia
Number of subjects: 128

Group type: COMPARATOR
Intervention: Propofol-based anaesthesia
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cerebral desaturation
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: No cerebral desaturation
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: General clinical outcome
Number of subjects: 128
Study: 19533753

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Covert placebo (CP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Overt placebo (OP)
Number of subjects: 10
Study: 15795700

Group type: EXPERIMENTAL
Intervention: Regimen A (omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + metronidazole 250 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Regimen B (omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + furazolidone 100 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Regimen C (omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + ciprofloxacin 500 mg bid)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Regimen A (in males)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Regimen B (in males)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Regimen B (in females)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Regimen C (in females)
Number of subjects: 245
Study: 10703873

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide/Triamterene (HT)
Number of subjects: 0
Study: 8953674

Group type: EXPERIMENTAL
Intervention: alpha-streptococci spray treatment for at least 5 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: placebo spray treatment for at least 5 days
Number of subjects: 130
Study: 1773094

Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6755544

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ioglicinate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ioglicinate-Lidocaine mixture
Number of subjects: 60
Study: 30877484

Group type: EXPERIMENTAL
Intervention: Duloxetine 30-60 mg per day for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pregabalin 75-150 mg per day for 4 weeks
Number of subjects: 0
Study: 29037092

Group type: EXPERIMENTAL
Intervention: Combined therapy (CT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dichotic listening training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Compensatory strategies
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 80
Study: 27118109

Group type: EXPERIMENTAL
Intervention: Pixantrone
Number of subjects: 97
Study: 24790069

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23106320

Group type: EXPERIMENTAL
Intervention: Polypropylene clips applied to the breech and tail of lambs
Number of subjects: 32028
Study: 20703230

Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg per day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Imidapril (2.5-10 mg per day) added to valsartan (160 mg per day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Valsartan (160 mg per day)
Number of subjects: 87
Study: 17434727

Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg b.i.d.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16362647

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (100 mg)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 11939923

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 125

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 125
Study: 9803047

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) oxycodone 30 mg every 12 hr
Number of subjects: 111

Group type: COMPARATOR
Intervention: Immediate-release (IR) oxycodone 15 mg four times daily
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both CR and IR oxycodone
Number of subjects: 111
Study: 8919986

Group type: EXPERIMENTAL
Intervention: Cumulative dosage method (group I, 33 patients)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 0.35 micrograms/kg (group II, 8 patients)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 50 micrograms/kg (group III, 12 patients)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 55
Study: 2550644

Group type: EXPERIMENTAL
Intervention: lisinopril 10 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: enalapril 10 mg
Number of subjects: 16
Study: 30692001

Group type: EXPERIMENTAL
Intervention: Dynamic milk model using PTA traits for milk yield, fat, and protein
Number of subjects: 1904
Study: 29185253

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study: 25673441

Group type: EXPERIMENTAL
Intervention: Formulation A (four-drug FDC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Formulation B (two-drug FDC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Formulation C (two-drug FDC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Formulation D (two-drug FDC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reference (free combinations)
Number of subjects: 38
Study: 25608545

Group type: EXPERIMENTAL
Intervention: Coaching Program on Comprehensive Lifestyle Modification
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 22743352

Group type: EXPERIMENTAL
Intervention: Mental health literacy and destigmatization condition
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Feedback condition
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Help-seeking list condition
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 59
Study: 20202537

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with micro-bypass stent implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phacoemulsification alone (control group)
Number of subjects: 0
Study: 17047022

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg weekly
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 15558082

Group type: COMPARATOR
Intervention: Staff perception of patients' emotional problems
Number of subjects: 29

Group type: COMPARATOR
Intervention: Staff perception of patients' family problems
Number of subjects: 29

Group type: COMPARATOR
Intervention: Staff perception of patients' coping ability
Number of subjects: 29

Group type: COMPARATOR
Intervention: Staff perception of patients' mental health
Number of subjects: 29

Group type: COMPARATOR
Intervention: Staff assessment of patients' physical symptoms
Number of subjects: 29

Group type: COMPARATOR
Intervention: Staff assessment of patients' functional limitations
Number of subjects: 29

Group type: COMPARATOR
Intervention: Staff assessment of patients' role problems
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Correlation between patient and staff ratings
Number of subjects: 29
Study: 12413331

Group type: EXPERIMENTAL
Intervention: Automated blood collection device (spring-loaded lance)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Manual lance
Number of subjects: 134
Study: 10215948

Group type: EXPERIMENTAL
Intervention: Asymptomatic HIV-positive haemophiliacs
Number of subjects: 38

Group type: COMPARATOR
Intervention: HIV-negative haemophiliacs
Number of subjects: 38
Study: 8746073

Group type: EXPERIMENTAL
Intervention: ipriflavone (IP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: salmon calcitonin (sCT)
Number of subjects: 40
Study: 2612203

Group type: EXPERIMENTAL
Intervention: Amoxycillin plus clavulanic acid (250 or 500 mg amoxycillin and 62.5 or 125 mg clavulanic acid) 3-times daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amoxycillin (250 or 500 mg) 3-times daily
Number of subjects: 100
Study: 338197

Group type: EXPERIMENTAL
Intervention: ICI 74,917 (0.5 mg in each nostril four times a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 24
Study: 31461393

Group type: EXPERIMENTAL
Intervention: Immediate Dentin Sealing (IDS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed Dentin Sealing (DDS)
Number of subjects: 60
Study: 28661696

Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction (DB group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction with bioabsorbable screw fixation (SBB group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction with metallic screw fixation (SBM group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 90

Group type: COMPARATOR
Intervention: Patients with longest delay from injury to reconstruction
Number of subjects: 90

Group type: COMPARATOR
Intervention: Patients who underwent partial meniscal resection
Number of subjects: 90
Study: 26203094

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Zinc + Multivitamin supplementation
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400
Study: 23757427

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) insulin delivery
Number of subjects: 12

Group type: COMPARATOR
Intervention: Open-loop (OL) control
Number of subjects: 12
Study: 21565820

Group type: EXPERIMENTAL
Intervention: Falls prevention program (intervention group)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study: 19620514

Group type: EXPERIMENTAL
Intervention: Slow sodium
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 17482982

Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg/day)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Liposomal amphotericin B (3 mg/kg per day)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 264

Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 264
Study: 15501783

Group type: EXPERIMENTAL
Intervention: 20- or 50-microg dose of alum-adsorbed ICC-1132 administered intramuscularly at 0, 2, and 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ICC-1132-alum
Number of subjects: 20
Study: 11675958

Group type: EXPERIMENTAL
Intervention: Arotinolol 10-20 mg twice daily for 4 weeks
Number of subjects: 47
Study: 9136230

Group type: EXPERIMENTAL
Intervention: Community intervention utilizing opinion leaders and educational strategies over 15 months.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Participation in at least one intervention program.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control communities (not specified in detail).
Number of subjects: 6
Study: 7701226

Group type: EXPERIMENTAL
Intervention: Localized aerosol hyperthermia (AH) with aerosol of 43 degrees C
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo device (PH) with aerosol of 32 degrees C
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Localized aerosol hyperthermia (AH)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo device (PH)
Number of subjects: 57
Study: 3542183

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (Intron A, Schering Corp., Kenilworth, NJ) 2 X 10(6) U/m2 subcutaneously, three times a week for 1 year
Number of subjects: 212

Group type: COMPARATOR
Intervention: Interferon alfa‐2b (Intron A, Schering Corp., Kenilworth, NJ) continued for 6 months
Number of subjects: 212
Study: 29142030

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) plus Methotrexate (MTX)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo plus Methotrexate (MTX)
Number of subjects: 180
Study: 27820670

Group type: EXPERIMENTAL
Intervention: Newcomer and traveler surveillance and treatment program in addition to annual mass drug administration (MDA)
Number of subjects: 5200

Group type: COMPARATOR
Intervention: Usual practice communities receiving MDA only
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: Overall population with TF
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: Households without a bicycle
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: Increasing child's age
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: Households >30 minutes from water
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: Increasing years of education
Number of subjects: 5200
Study: 25621884

Group type: EXPERIMENTAL
Intervention: 3.75 μg of A/H1N1 antigen formulated with 50% MF59 (3.75_halfMF59)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: 7.5 μg of A/H1N1 antigen formulated with 100% MF59 (7.5_fullMF59)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Nonadjuvanted 15 μg A/H1N1 antigen
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: 7.5_fullMF59
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: 3.75_halfMF59
Number of subjects: 666
Study: 23086524

Group type: EXPERIMENTAL
Intervention: Rapid weight loss (RWL) preparation with very low calorie diet
Number of subjects: 28
Study: 21905025

Group type: EXPERIMENTAL
Intervention: Written disclosure
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Private spoken disclosure
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Talking to a passive listener
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Talking to an active facilitator
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: All groups (disclosure and control)
Number of subjects: 214
Study: 18238794

Group type: EXPERIMENTAL
Intervention: Testosterone patches (150 microg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 34
Study: 16603244

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 46

Group type: COMPARATOR
Intervention: Gatifloxacin 0.3% ophthalmic solution
Number of subjects: 46
Study: 15537995

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Therapy (CIT) for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Delayed treatment group (no therapy for 2 weeks)
Number of subjects: 10